Arrowhead Pharmaceuticals (ARWR) CMO granted 75,000 RSUs in filing

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals Chief Medical Officer reports stock award. On 01/06/2026, Chief Medical Officer James C. Hamilton was granted 75,000 shares of Arrowhead Pharmaceuticals common stock underlying restricted stock units at a price of $0 per share.

These restricted stock units will vest in four equal annual installments. Following this award, Hamilton beneficially owned 246,958 shares of common stock, including previously reported shares underlying restricted stock units, some of which remain subject to vesting conditions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hamilton James C

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	75,000	$0.00	--

Holdings After Transaction: Common Stock — 246,958 shares (Direct)

Footnotes (1)

1. Represents shares underlying restricted stock units which will vest in four equal annual installments. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamilton James C

(Last) (First) (Middle)

177 EAST COLORADO BLVD

SUITE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		75,000(1)	A	$0	246,958(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units which will vest in four equal annual installments.

2. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/James Hamilton	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ARWR report for James C. Hamilton?

Arrowhead Pharmaceuticals reported that Chief Medical Officer James C. Hamilton was granted 75,000 shares of common stock underlying restricted stock units on 01/06/2026 at a price of $0 per share.

What is James C. Hamilton’s role at Arrowhead Pharmaceuticals (ARWR)?

James C. Hamilton is an officer of Arrowhead Pharmaceuticals, serving as the company’s Chief Medical Officer.

How many ARWR shares does James C. Hamilton beneficially own after this transaction?

After the reported grant, James C. Hamilton beneficially owned 246,958 shares of Arrowhead Pharmaceuticals common stock.

What are the vesting terms for the 75,000 Arrowhead Pharmaceuticals RSUs?

The 75,000 shares represent restricted stock units that will vest in four equal annual installments, according to the footnote.

What type of security was involved in this ARWR Form 4 filing?

The filing reports a grant of Arrowhead Pharmaceuticals common stock in the form of restricted stock units to the Chief Medical Officer.

Was the reported Arrowhead Pharmaceuticals transaction a purchase or an award?

The transaction code is “A”, indicating an acquisition of shares, and the footnote clarifies this was an equity award of restricted stock units at $0 per share.